PRESSURE BIOSCIENCES INC
PBIOHealthcare · Laboratory Analytical Instruments · MA · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | |
|---|---|---|---|---|---|---|
| Revenue | $2.0M | $1.7M | $2.0M | $1.2M | $1.8M | $2.5M |
| Operating income | −$9.5M | −$4.9M | −$4.2M | −$4.6M | −$5.8M | −$4.5M |
| Net income | −$29.3M | −$16.1M | −$20.2M | −$16.0M | −$11.7M | −$9.7M |
| Total assets | $1.0M | $2.0M | $2.8M | $2.3M | $1.8M | $2.4M |
| Total liabilities | $33.8M | $34.7M | $25.0M | $19.2M | $13.9M | $8.5M |
| Equity | −$32.8M | −$32.7M | −$22.2M | $473,027 | −$12.1M | −$6.1M |
| EPS (diluted) | $-1.51 | $-1.61 | $-3.42 | — | — | — |
| Shares out. | 15.9M | 8.7M | 4.3M | 2.8M | 1.7M | 1.4M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2023- Operating margin
- −480.5%
- Net margin
- −1482.2%
- Return on equity
- 89.5%
- Return on assets
- −2792.7%
- Return on capital (ROCE)
- —
- Liabilities / assets
- 3220.4%
- Debt / equity
- —
- Book value / share
- $-2.06
- Revenue growth (YoY)
- 14.4%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2023- Altman Z″ (distress)
- -791.90distress
- Accruals / assets
- −2489.2%clean
- Piotroski F-Score
- 2/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 3 severe● 4 warning● 3 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Strong return on equity (>15%)
- Revenue is growing year-over-year
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗Aug 19, 2024
- NT 10-Qmissed a reporting deadline ↗May 17, 2024
- NT 10-Kmissed a reporting deadline ↗Apr 1, 2024
- NT 10-Qmissed a reporting deadline ↗Nov 15, 2023
- NT 10-Qmissed a reporting deadline ↗Aug 15, 2023
- NT 10-Kmissed a reporting deadline ↗Apr 3, 2023
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| Sep 15, 2025 | 13 | 1.0 | 0.0% |
| Aug 29, 2025 | 13 | 1.0 | 0.0% |
| Aug 15, 2025 | 13 | 1.0 | 0.0% |
| Jul 31, 2025 | 13 | 1.0 | 0.0% |
| Jul 15, 2025 | 13 | 1.0 | 0.0% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Other material eventJul 17, 2024
- Director / officer changeJul 3, 2024
- Shareholder voteApr 22, 2024
- Entered a material agreement · Other material eventJan 25, 2024
- Director / officer changeOct 24, 2023
- Amended charter or bylawsMay 5, 2023
- Entered a material agreement · Unregistered equity saleMar 6, 2023
- Shareholder voteJan 5, 2023
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.